James N. Kochenderfer, M.D.

James N. Kochenderfer, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Surgery Branch


Dr. Kochenderfer is a physician-scientist working to develop immunotherapies for lymphoma, leukemia, and multiple myeloma. His current work focuses on chimeric antigen receptor T-cell therapies. Chimeric antigen receptors (CARs) are fusion proteins that recognize malignant cells. T cells genetically engineered to express CARs can be infused into patients to treat cancer. Dr. Kochenderfer leads laboratory studies of CAR T-cell biology and clinical studies of CAR T-cell therapies for multiple myeloma and for treatment of B-cell malignancies after allogeneic hematopoietic stem cell transplantation.

Areas of Expertise

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them. 


Selected Recent Publications

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN
N Engl J Med. 380: 1726-1737, 2019. [ Journal Article ]

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, Stetler-Stevenson M, Salem D, Yuan C, Pavletic S, Kanakry JA, Ali SA, Mikkilineni L, Feldman SA, Stroncek DF, Hansen BG, Lawrence J, Patel R, Hakim F, Gress RE, Kochenderfer JN.
J Clin Oncol. 36/22: 2267-2280, 2018. [ Journal Article ]

Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7.

Amatya C, Pegues MA, Lam N, Vanasse D, Geldres C, Choi S, Hewitt SM, Feldman SA, Kochenderfer JN
Mol Ther.. 3;29(2: 702-717, 2020. [ Journal Article ]

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, Roschewski M, Dean R, Cachau R, Youkharibache P, Patel R, Hansen B, Stroncek DF, Rosenberg SA, Gress RE, Kochenderfer JN
Nature Medicine. 26(2): 270-280, 2020. [ Journal Article ]

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains.

Lam N, Trinklein ND, Buelow B, Patterson GH, Ojha N, Kochenderfer JN
Nat Commun.. 15;11(1):: 283, 2020. [ Journal Article ]

Job Vacancies

We have no open positions in our group at this time, please check back later.

To see all available positions at CCR, take a look at our Careers page. You can also subscribe to receive CCR's latest job and training opportunities in your inbox.


Postdoctoral Fellow (Visiting)
Christina Amatya, Ph.D.
Medical Oncology Clinical Fellow
Kathryn Cappell, M.D.
Research Nurse
Micaela Ganaden, R.N.
Norris Lam, B.S.
Nurse Practitioner
Jennifer Mann, CRNP
Patient Care Coordinator (Contr.)
Rachael Mohn, B.S.
Research Technician (Contr.)
Danielle Vanasse, B.S.
Visiting Fellow
Lauren Cutmore, Ph.D
Research Nurse
Genevieve Fromm, BSN, RN
Kathryn Weissler, Ph.D.